Zhigang Cai

Dr. Zhigang Cai


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
HLHaining Li
Haining Li
LGLiping Guo
Liping Guo
ZCZhigang Cai
Zhigang Cai
Background: Around the world, lung cancer is the leading cause of cancer-related death. Lung adenocarcinomas are among the most common diagnosed forms of lung cancer, whose overall survival has not improved significantly, which makes finding an effective therapeutic target vital. Transcobalamin (TCN1) is a vitamin B12-binding protein which regulates cobalamin homeostasis. In tumor tissues, TCN1 is expressed highly, and its expression is correlated with cancer aggressiveness and poor prognosis according to recent studies and bioinformatic analyses. However, its effect on lung adenocarcinoma (LUAD) is unknown. Methods: We evaluated whether TCN1 shows diagnostic and prognostic value in LUAD using bioinformatic analysis. In particular, various databases and analysis tools were used to determine TCN1’s relationship with LUAD, including TCGA, GTEx, GEO, STRING, and TISIDB. Results: As compared to normal lung tissue, the level of TCN1 expression in LUAD tissues was significantly higher (P < 0.001). TCN1 also had a good ability to distinguish lung adenocarcinoma from non-lung adenocarcinoma samples [area under the curve (AUC) = 0.788]. According to univariate Cox statistics, high expression levels of TCN1 correlate with poor overall survival (OS) in LUAD (P < 0.001). Moreover, based on a multivariate Cox analysis, TCN1 expression was independently correlated with OS (P = 0.011). GO/KEGG and GSEA indicated enrichment in epidermal cell differentiation (P < 0.0005), keratinocyte differentiation (P < 0.0005), neuroactive ligand–receptor interaction (P < 0.0005), epithelial–mesenchymal transition (P = 0.029, FDR = 0.023) and TNFA signaling via NFKB (P = 0.029, FDR = 0.023). Furthermore, TCN1 is associated with immune infiltration based on an analysis of immune cell infiltration. Conclusions: In summary, TCN1 could be used as a prognostic and diagnostic biomarker and provide deeper perspectives for the development of therapies and prognostic markers in LUAD.

14 November 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
SZShusen Zhang
Shusen Zhang
ZCZhigang Cai
Zhigang Cai
HLHui Li
Hui Li
The AHNAK family currently consists of two members, namely AHNAK and AHNAK2, both of which have a molecular weight exceeding 600 kDa. Homologous sequences account for approximately 90% of their composition, indicating a certain degree of similarity in terms of molecular structure and biological functions. AHNAK family members are involved in the regulation of various biological functions, such as calcium channel modulation and membrane repair. Furthermore, with advancements in biological and bioinformatics technologies, research on the relationship between the AHNAK family and tumors has rapidly increased in recent years, and its regulatory role in tumor progression has gradually been discovered. This article briefly describes the physiological functions of the AHNAK family, and reviews and analyzes the expression and molecular regulatory mechanisms of the AHNAK family in malignant tumors using Pubmed and TCGA databases. In summary, AHNAK participates in various physiological and pathological processes in the human body. In multiple types of cancers, abnormal expression of AHNAK and AHNAK2 is associated with prognosis, and they play a key regulatory role in tumor progression by activating signaling pathways such as ERK, MAPK, Wnt, and MEK, as well as promoting epithelial-mesenchymal transition.

23 June 2022 in Frontiers in Genetics
Verified
Journal Article
Open access
YHYanpeng He
Yanpeng He
CZChunyan Zou
Chunyan Zou
ZCZhigang Cai
Zhigang Cai
Objective: To explore the possible biological functions of the differentially expressed genes in patients with benign tracheal stenosis, and to provide a valuable molecular basis for investigating the pathogenesis of benign tracheal stenosis.Method: Whole transcriptome sequencing was performed on blood samples collected from patients with benign tracheal stenosis and normal controls. Differentially expressed mRNA, lncRNA, and circRNA were analyzed using the DESeq2 package. The protein interaction networks for differentially expressed mRNAs were constructed by STRING. The results of gene co-expression network analysis, Starbase database prediction, and differential gene expression were combined to construct a competing endogenous RNA network. The transcription factors of key genes were predicted using the Network Analyst database and a transcription factor-mRNA regulatory network was constructed. The classical pathways, intermolecular interaction networks, and upstream regulatory components of key genes were analyzed using Ingenuity Pathway Analysis (IPA). Finally, the DGIDB database was used to predict the potential therapeutic drugs to target the identified key genes.Result: Based on mRNA, lncRNA and circRNA expression data, we found that differentially expressed mRNAs were enriched in oxygen transport, neutrophil activation, immune response, and oxygen binding. Then the pearson correlation between mRNAs of 46 key genes and lncRNAs and cricRNAs were calculated, and the correlation greater than 0.9 were selected to construct the co-expression network of “mRNA-lncRA” and “mRNA-cricRNA.” Moreover, a “lncRNA-miRNA-mRNA” network and a “circRNA-miRNA-mRNA” network were constructed. IPA analysis showed that the 46 key genes were significantly associated with inflammatory activation and acute respiratory distress syndrome. The constructed TF-mRNA regulatory network was composed of 274 nodes and 573 interacting pairs. 251 potential therapeutic drugs were identified from the DGIDB database.Conclusion: This study analyzed the differential genes associated with benign tracheal stenosis and explored the potential regulatory mechanisms, providing a scientific reference for further studies on the pathogenesis of benign tracheal stenosis.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SZShusen Zhang
Shusen Zhang
YLYuanyuan Lu
Yuanyuan Lu
LQLei Qi
Lei Qi
HWHongyan Wang
Hongyan Wang
ZWZhihua Wang
Zhihua Wang
ZCZhigang Cai
Zhigang Cai
Background. Lung adenocarcinoma (LUAD), as the main subtype of lung cancer, is one of the common causes of cancer‐related deaths worldwide. The AHNAK family is correlated with cell structure and migration, cardiac calcium channel signaling, and tumor metastasis. Previous studies showed AHNAK2 could promote tumor progression and cell migration in melanoma and renal clear cell carcinoma. However, the role of AHNAK2 in LUAD remains unknown. Methods. We examined the levels of AHNAK2 in pathological specimens and the database of Clinical Proteomic Tumor Analysis Consortium‐Lung adenocarcinoma (CPTAC‐LUAD), The Cancer Genome Atlas‐Lung Adenocarcinoma (TCGA‐LUAD), Gene Expression Omnibus dataset (GSE72094, GSE26939), and The Genotype‐Tissue Expression (GTEx) of lung tissue samples. Univariate Cox regression, multivariate Cox regression, and Kaplan–Meier survival analysis were performed to reveal the relationship between AHNAK2 and prognosis. A nomogram was constructed to predict 2‐ or 3‐year overall survival and validated via calibration curves, receiver operating characteristic (ROC) analysis, and decision curve analysis (DCA). Furthermore, Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were used to explore the functional role of AHNAK2 in lung adenocarcinoma. Finally, by transfecting siRNA, we examined the regulatory effect of AHNAK2 on cell migration. Results. The expression of AHNAK2 was upregulated in tumor samples and correlated with poor prognosis in LUAD patients. Nomogram with AHNAK2 and clinical parameters showed a good prediction in overall survival (OS), especially the 2‐year OS. In addition, functional analyses and wound healing assay suggested that AHNAK2 might be involved in the regulation of migration in LUAD. Conclusion. In summary, our study showed that AHNAK2 might be a novel biomarker in LUAD and revealed the potential mechanism of AHNAK2 in LUAD progression which could provide new insights for target therapy.

16 May 2025 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
YLYaqing Li
Yaqing Li
JXJianping Xu
Jianping Xu
LZLijuan Zhang
Lijuan Zhang
ZCZhigang Cai
Zhigang Cai
Immune and inflammation participate in the progression of non-small cell lung cancer (NSCLC) and some immune-inflammation indexes may serve as prognostic biomarkers in NSCLC patients. This study aimed to investigate the association between immune-inflammation indices at multiple time points and prognosis in advanced NSCLC patients treated with immune checkpoint inhibitors (ICIs). This retrospective study included 102 advanced NSCLC patients treated with ICIs and collected their blood indices within 7 days before treatment (T1), before the 3rd treatment cycle (T2), and before the 5th treatment cycle (T3) to calculate neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), pan-immune-inflammatory value (PIV), systemic immune-inflammation index (SII), prognostic nutritional index (PNI), and lung immune prognostic index (LIPI). dNLR (P = 0.006), SII (P = 0.005), PIV (P = 0.010), and LIPI (P = 0.001) reduced, while PNI increased (P = 0.009) from T1 to T3; NLR was not different among T1, T2, and T3 (P = 0.282). A lower NLR (P = 0.011) and higher PNI (P = 0.026) at T3, and lower LIPI at T2 (P = 0.023) were related to better disease control rate, but these immune-inflammation indices were not linked with objective response rate at any timepoint. Multivariate Cox regression analysis showed that high NLR at T1 was independently related to worse PFS (hazard ratio: 4.187, P = 0.008), while high PNI at T3 was independently associated with better PFS (hazard ratio: 0.454, P = 0.021). NLR before and after treatment, as well as PNI and LIPI after treatment may serve as potential biomarkers for treatment response or survival in advanced NSCLC patients receiving ICIs.

1 October 2020 in Journal of Computational Biology
Verified
Journal Article
Closed access
SZShusen Zhang
Shusen Zhang
YLYuanyuan Lu
Yuanyuan Lu
ZLZhongxin Liu
Zhongxin Liu
XLXiaopeng Li
Xiaopeng Li
ZWZhihua Wang
Zhihua Wang
ZCZhigang Cai
Zhigang Cai
Metabolic genes have been reported to act as crucial roles in tumor progression. Lung adenocarcinoma (LUAD) is one of the most common cancers worldwide. This study aimed to predict the potential mechanism and novel markers of metabolic signature in LUAD. The gene expression profiles and the clinical parameters were obtained from The Cancer Genome Atlas-Lung adenocarcinoma (TCGA-LUAD) and Gene Expression Omnibus data set (GSE72094). A total of 105 differentially expressed metabolic genes of intersect expression in TCGA-LUAD and GSE72094 were screened by R language. Univariate Cox regression model found 18 survival-related genes and then the least absolute shrinkage and selection operator model was successfully constructed. Six significant genes prognostic model was validated though independent prognosis analysis. The model revealed high values for prognostic biomarkers by time-dependent receiver operating characteristic (ROC) analysis, risk score, Heatmap, and nomogram. In addition, Gene Set Enrichment Analysis showed that multiplex metabolism pathways correlated with LUAD. Furthermore, we found the six genes aberrantly expressed in LUAD samples. Our study showed that metabolism pathways play important roles in LUAD progression. The six metabolic genes could predict potential prognostic and diagnostic biomarkers in LUAD.